Continuous Subcutaneous Apomorphine Infusion in Parkinson’s Disease: A Single-Center, Long-Term Follow-Up Study of the Causes for Discontinuation

(1) Background: Subcutaneous apomorphine infusion (SCAI) is one of the three main treatment options for motor fluctuations in advanced Parkinson’s disease (PD). The adherence to SCAI is generally considered to be low due to adverse events and because it is perceived as a treatment option to be used...

Descripción completa

Detalles Bibliográficos
Autores principales: Henriksen, Tove, Staines, Harry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8226743/
https://www.ncbi.nlm.nih.gov/pubmed/34201198
http://dx.doi.org/10.3390/jpm11060525

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8226743/
https://www.ncbi.nlm.nih.gov/pubmed/34201198
http://dx.doi.org/10.3390/jpm11060525

Ejemplares similares